Criteria for Drugs Used in Pre-Exposure Prophylaxis Trials against HIV Infection
Author Information
Author(s): Inge Derdelinckx, Mark A. Wainberg, Joep M. A. Lange, Andrew Hill, Yasmin Halima, Charles A. B. Boucher
Primary Institution: University Medical Center, Eijkman Winkler Institute, Department of Virology, Utrecht, Netherlands
Hypothesis
What criteria should an optimal pre-exposure prophylaxis drug candidate meet?
Conclusion
The study argues that 3TC could be a promising pre-exposure prophylaxis drug due to its safety, ease of use, and cost-effectiveness.
Supporting Evidence
- 3TC has a favorable safety profile based on extensive clinical experience.
- The study emphasizes the need for a high genetic barrier in PREP drugs to prevent virologic failure.
- Cost-effectiveness analysis shows that PREP with generic 3TC could be cost-effective in preventing HIV infections.
Takeaway
This study looks at what makes a good medicine to help prevent HIV. It suggests that a drug called 3TC could be a good choice because it's safe and easy to take.
Methodology
The authors formulated criteria for an optimal PREP drug candidate based on a literature review and expert opinion.
Limitations
The study lacks data from randomized controlled clinical trials to validate the proposed criteria.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website